STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, although we do plan to escort Mrs. Pharmalot to a sing-a-long, attend a food crawl, and promenade with the official mascots. We also hope to find time to indulge in another listening party where the rotation will likely include this, this, this, this and this. And what about you? This is a lovely time of year to appreciate the great outdoors, specifically a stroll or jalopy ride to gaze at the turning of the leaves. If the weather fails to cooperate, you could catch up on your reading or take in a moving picture show. Or now that the elections are over in the U.S., you may want to place a bet on what the future holds. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. … Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, a surprising development that has raised concerns among families, physicians, and patient advocacy groups, STAT writes. The cases, which for the moment are being seen as only a potential safety signal, were publicized on Thursday by an advocacy group and on a Facebook page after Novartis earlier this week disclosed the information to neurologists. One advocacy group, SMA Europe, issued a statement saying that regulatory authorities are now examining the cases. Four of the eight people appointed by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. to an influential health panel in September own stock in companies that make drugs and other products affected by the group’s decisions, The New York Times reports. The investments were described in conflict-of-interest waivers that gave the members permission to serve on the panel, the U.S. Preventive Services Task Force, which evaluates evidence for services like colonoscopies, HIV prevention drugs, depression screening, and more. Its recommendations both inform physician decisions and determine what insurers must pay. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe